Abstract. The expression of angiogenesis-related proteins was determined in laryngeal tumour tissue, associated tumour involved lymph nodes, apparently normal mucosa and control tissue and were related to tumour stage. Both laryngeal tumour tissue and associated metastatic nodes were obtained from seven patients undergoing surgical resection; in four cases apparently normal mucosa was also dissected from the tumour specimen margins. Control uvula mucosa was obtained from five healthy volunteers undergoing uvulopalatopharyngoplasty. The relative expression of 55 angiogenesis-related proteins was determined in tissue lysates using a Proteome Profiler human angiogenesis array kit. The level of 32/55 angiogenesis-related proteins was higher in tumour tissue compared with controls. Furthermore, in these tumour biopsies higher levels of proteins were associated with increasing tumour stage. A similar trend was seen for 29/32 of these proteins in the nodal tissue. In T4 stage tumour tissue samples, 29/55 angiogenensis-related proteins were more highly expressed compared with the adjacent normal mucosa from the same patient, and this decreased to 8 proteins in tumour tissue from the T1 stage patients. In contrast, the expression of 23 angiogenesis-related proteins in metastatic lymph node tissue from T4 stage patients was lower compared with that found in the normal mucosa adjacent to the tumour. In conclusion, this study has identified a number of factors involved in angiogenesis that are likely to contribute to the growth and metastasis of laryngeal tumours. Furthermore, a number of factors were also substantially altered in metastatic deposits compared with the primary tumour mass or adjacent normal tissue. This study requires confirmatory analysis of the selected key factors in a larger cohort of patients.
Introduction
Head and neck squamous cell carcinoma (HNSCC), a term comprising a heterogeneous group of aggressive, mainly epithelial malignancies, represents the sixth most common solid tumour worldwide (1) . HNSCC arises in distinct anatomical sites displaying varied histologies and clinical courses with tobacco and alcohol being the most common aetiological risk factors. Treatment usually involves a combination of surgery, chemo-and radiotherapy. Unfortunately both the anatomical location of the tumour and the subsequent treatment can severely affect a patient's quality of life, i.e., swallowing, breathing and speaking may all become difficult (2) .
Although recent reports indicate a better prognosis for patients with human papilloma virus (HPV) positive oropharyngeal tumours (3), 5-year survival rates for HNSCC patients with HPV negative tumours remain less than 50%. This is despite advances in treatment, and is mainly due to late presentation, early loco-regional recurrence of the tumour and the development of second primaries (4) . Advanced tumour stage and lymph node spread are widely accepted as the two strongest poor prognostic factors for HNSCC, although the relevance of a growing number of molecular markers are being investigated (5) .
The concept of field cancerization was first introduced by Slaughter et al (6) who postulated that normal mucosa has the potential to undergo malignant transformation at multiple sites due to assault from various aetiological agents. The 'field of cancerization' is currently viewed as an area of cells in which a single stem cell, that has acquired initiating mutations caused by carcinogens, has given mutation to the daughter cells that grow out to form a patch and then a wider 'field' of premalignant cells (7) .
In order for a tumour to grow and metastasise it needs to develop its own blood supply by a process known as angiogenesis. Factors secreted by both tumour and stroma stimulate the surrounding endothelial cells to form new blood vessels. Angiogenesis does not result from the action of a single growth factor, but is dependent on the interaction of multiple proteins with angiogenic properties. In HNSCC, like almost all other solid tumours, factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF) and platelet derived growth factor (PDGF) have been shown to induce angiogenesis and are negative prognostic factors for patient survival (8) .
VEGF is the most widely studied angiogenic factor and is considered a key regulator of tumour-induced angiogenensis. The VEGF family consists of several factors known to act directly on vascular endothelial cells stimulating formation of new blood vessels (9) . However, more recently it has been shown that VEGF proteins are also involved in tumour progression, immune-suppression and immune-tolerance (10) . Similarly, FGF plays a role in angiogenesis by inducing endothelial proliferation and by regulating proteases like uPA and PAI-1 (11, 12) . Similarly, PDGF stimulates angiogenesis, plays a crucial role in tumour growth and raised levels have has been correlated with VEGF in HNSCC (13, 14) .
A recent phase I/II clinical trial by Cohen and colleagues (15) , investigated the efficacy of anti-angiogenic therapies and demonstrated that a combination of erlotinib (epidermal growth factor receptor inhibitor) and bevacizumab (anti-VEGF antibody) is well tolerated in recurrent metastatic HNSCC (15) . A better understanding of the network of angiogenic proteins present in distinct subsets of HNSCC is necessary, however, to underpin further anti-angiogenic therapies.
The aim of the current study was to investigate the expression of a panel of angiogenesis-related proteins in laryngeal tumour tissue, associated metastatic nodes and clinically normal mucosa from the same patient, in comparison with their expression in control uvula mucosa. The results were also correlated with tumour stage with a view to identifying potential markers of HNSCC cancer progression and metastatic spread.
Materials and methods
Patients and samples. Newly-presenting patients with mode rately differentiated squamous cell carcinoma of the larynx (T1N2, n=2; T3N1, n=1; T3N2, n=1; T4N2, n=3) were recruited into the study. Following written informed consent, and prior to chemotherapy and radiotherapy, fresh tissue specimens were obtained intraoperatively from the tumour (n=7) and secondary lymph node (n=7). Where possible, normallooking mucosa was also dissected away from the resected tumour specimen (n=4). Patients were all male with a mean age of 66.4 (range 46-85) years. A sample of control uvula mucosa (n=5) was removed from healthy volunteers undergoing surgery for uvulopalatopharyngoplasty. Approval for the study was gained from both the South Humber Research Ethics committee and Hull and East Yorkshire Hospitals R&D (06/Q1105/63 and 07/H1305/70).
Lysate preparation. Tissue was transported to the laboratory in Dulbecco's Modified Eagle's Medium (DMEM; PAA, Somerset, UK), supplemented with 10% (v/v) fetal bovine serum (FBS; Biosera, East Sussex, UK), penicillin/streptomycin (final concentrations: 0.1 U/ml, 0.1 mg/ml, respectively PAA). Tissue lysates were prepared by finely mincing the tissue, on ice, using scalpels in ProteoJET mammalian cell lysis reagent (500 µl/100 mg tissue; Fermentas Life Sciences, York, UK), containing protease inhibitor cocktail (1 ml/20 g tissue; Calbiochem/Merck, Nottingham, UK). The lysate was then subjected to sonication for 15 min on ice before centrifugation at 400 x g for 15 min to pellet cell debris. The resulting supernatant was aliquoted into 0.5 ml lysates and stored at -80˚C for antibody array processing.
Protein determination and antibody array. The protein concentration in each lysate was quantified immediately before use in the antibody array using the Coomassie Brilliant Blue plus assay kit (Thermo Scientific, Pierce, Rockford USA) following the manufacturer's instructions. The relative expression of 55 angiogenesis-related proteins was determined in each lysate using a Proteome Profiler™ human angiogenesis array kit (R&D Systems, Abingdon, UK) following the manufacturer's protocol. Briefly, following blocking of the nitrocellulose membrane spotted with antibodies against angiogenesis-related proteins, 200 µg of lysate was mixed with a cocktail of biotinylated detection antibodies (15 µl) and added to the membrane before incubating overnight at 4˚C. Streptavidin-horseradish peroxidase (HRP, 1.5 ml) was then added to the membrane, incubated for 30 min before chemiluminescence detection reagents were added in equal volumes for 1 min. Residual detection reagent was carefully blotted off the membrane before covering it in plastic wrap and exposing to X-ray film for 5 and 10 min (Fig. 1) . The light produced at each spot is proportional to the amount of analyte bound and the average pixel density of the duplicate spots produced on the film was determined using a UVP Bio-Imaging system fitted with LabWorks 4.0 Image acquisition and analysis software.
In addition to the 55 angiogenesis-related proteins, the membrane contained three pairs of positive control and one pair of irrelevant negative control antibodies. Following subtraction of the average optical density of the negative control spots from Table I . Percent expression of angiogenic factors from stage T1 to stage T4 in tumour and nodal tissue. factor  T1  T3  T4  T1  T3  T4   Serpin E1   c   46 124 159 62  62  110  Serpin F1  21  56  33 ND  22  45  TIMP1  117 all values, the level of the angiogenesis-related proteins were expressed as a percentage relative to the mean of the positive controls, which was assigned a value of 100%. The mean optical density and the standard deviation (SD) for the six positive control spots were determined for each of the membranes (n=7) studied and the SD was found to be ~20% in all cases. Therefore factors, which had an expression level within 20% of the positive control in all the T stages, were deemed not to have altered protein levels (n=15, Table I ).
Relative expression of all 55 angiogenesis-related proteins was compared between: i) tumour and lymph node from the same patient (n=7) and uvula control tissue (n=5); ii) clinically normal looking mucosa (n=4), and malignant tissue (tumour and node); and iii) clinically normal looking mucosa and uvula control mucosa (n=5).
Results
Comparison of angiogenesisrelated protein expression between tumour tissue and corresponding lymph node. Fifteen of the 55 angiogenesis-related factors showed no changes in expression (within 20% of positive control) across all T stages and were not further examined (Table I) . Forty of the 55 angiogenesisrelated factors investigated demonstrated a level of expression which was >20% of the positive control in at least one tumour stage. Of these 40 angiogenesis-related proteins 32 showed an increase from stage T1 through T4 (Table I) . In most samples expression was detectable in all samples at all stages, alternatively in some cases it only became detectable in stage T3 (and then increased in T4), or was only present in T4. The same overall trend was observed for 29/32 of these factors in the nodal tissue from the same patient (excluding platelet factor 4, MMP-9 and IGFBP-1 which showed a variable expression through the stages). An example of the increasing trend is illustrated in Fig. 2A .
Tumour tissues from stage T3 and stage T4 patients had a higher relative expression of 31 (excluding thrombospondin-1) of the 32 angiogenesis-related proteins compared with the corresponding nodal tissues. Tumour tissues from stage T1 patients also showed a higher relative expression of 29 (excluding endoglin, platelet factor 4 and serpin E1) of the 32 proteins compared with the corresponding nodal tissue, although the level of difference was less apparent than at the advanced stages (Table I) .
Of the remaining 8 proteins, which had detectable levels, angiogenin and TIMP1, showed a consistent decrease in expression in tumour tissue from stage T1 to stage T4 (Fig. 2B) . These proteins in the corresponding nodal tissue showed variable expression; with higher expression in stage T1 and stage T4 tumours (Table I) . Table II . Angiogenesis-related proteins which demonstrate increasing expression in normal mucosa with advancing tumour stage of the patient (matched samples).
Comparison of angiogenesisrelated protein expression between tumour patients (HNSCC primary and associated lymph nodes
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T3 ( mucosa, tumour and metastatic nodal tissue from the same patient were obtained in four cases (T1, n=1; T3, n=2; T4, n=1). Eleven of the 40 angiogenesis-related proteins analysed increased in relative expression in normal looking mucosa with increasing tumour stage of the patient from which the normal tissue was obtained (Table II) .
Of the 40 angiogenesis-related factors analysed there were only 8 which had a higher relative expression in tumour tissue from T1 patients compared to normal mucosa from the same patient, however the number of factors with a higher expression in the tumour tissue compared to the normal mucosa increased in the later stage tumours (T3, n=32; and T4, n=29). Table III . Angiogenesis-related protein expression in normal mucosa compared with matched samples of tumour and nodal tissue. Angiogenic factor  T1  T3  T4  T1  T3  T4  T1  T3  T4 Actin A In contrast expression of some angiogenesis-related proteins in tumour adjacent normal tissue was higher than in the nodal tissue from the same patient: out of the 40 angiogenesis-related factors analysed, 24 showed a higher expression in normal mucosa from T4 patients compared with the corresponding node, whereas adjacent normal mucosa from stage T3 and stage T1 biopsies had 10 and 18 factors, respectively which showed a higher expression than the corresponding nodal tissue (Table III) .
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Comparison of angiogenesisrelated protein expression between normal looking mucosa and uvula control tissue. Nine of the 40 angiogenesis-related proteins analysed had a higher relative expression in normal mucosa obtained from the tumour patient compared with control uvula tissue (Table IV) . Of these nine factors, FGF acidic, FGF basic, IGFBP-2 and serpin B5 were also higher in normal mucosa compared with the nodal deposits (Table III) .
Discussion
A number of proteins are known to play an important role in angiogenesis, which is vital for the growth and advancement of solid tumours. Many studies have demonstrated the production of angiogenic proteins by HNSCC; however, the majority of these have only explored the expression of a single angiogenic factor (13, 16, 17) . To date there have been only four studies which have looked at multiple angiogenesis-related factors in lysates of HNSCC (8, (18) (19) (20) .
The current pilot study has investigated the expression of a panel of angiogenesis-related proteins in lysates from tumour tissue, associated lymph nodes, adjacent normal mucosa and uvula mucosa from normal controls. It was found that a large number of these proteins increase in expression in both tumour and metastatic nodes with increasing disease stage and therefore may be involved in promoting tumour progression. In addition we have shown that there is increased expression of some of these factors in the normal mucosa adjacent to the tumour compared with both the metastatic nodal tissue and uvula control tissue, suggesting that the processes may be occurring in a wider area than just the main tumour mass, potentially predisposing the patient to recurrence or the development of a second primary tumour supporting the 'field of cancerization' hypothesis. The angiogenic growth factors VEGF, IL-8, bFGF, HGF are commonly found to be overexpressed in HNSCC in lysates (8) and systemically (21, 22 ). In the current study 32 of the 40 angiogenesis-related proteins analysed had an increasing expression in the tumour tissue with advancement of the tumour stage. This is in agreement with previous studies in HNSCC, which showed increased expression of VEGF (18, 23) , MMP-9 (24) HGF and FGF (8) in tissue lysates with tumour progression. However, the current study has identified many more.
In a study which looked into multiple angiogenesisrelated growth factors, Ninck et al (20) reported an increased expression of a combination of factors in 80% of the HNSCC tumours and identified a distinct pattern of secretion which always included either VEGF or PDGF-AB, with G-CSF or GM-CSF. Montag et al (8) studied the expression of eight angiogenic factors in tissues and reported detectable expression of at least 4 factors in 90% of the tumours. In addition there was a significant association between factors VEGF-A and PDGF-BB two of the most common factors and with bFGF, HGF or G-CSF as well as with PDGF-AB. Chen et al (18) investigated the expression of angiogenic factors in tumour tissue, HNSCC cell lines and serum and established that the factors IL-8, VEGF, GM-CSF and a number of other pro-inflammatory cytokines (not included in the current angiogenesis array) produced by HNSCC are consistent with the pathology of the neoplasm. Petruzzelli et al (19) studied the expression of bFGF, VEGF, TGF and PGE2 in HNSCC cell lines and reported that HNSCC produce these factor(s) to stimulate endothelial cell proliferation and that VEGF may be involved in HNSCC-induced endothelial cell mitogenesis. In the current study it has been observed that a panel of proteins showed increased expression in tumour and associated nodes with the progression of tumour stage. However, further studies of large cohort of HNSCC patients should be considered to validate the significance of these factors.
In addition we demonstrated a higher level of expression in many of the angiogenic factors in both the tumour tissue and the associated nodal tissue, compared with tissue from the healthy control group, which is in accordance with previous studies where angiogenic factor levels of MMP-9 (24), HGF, VEGF (21, 25) and IL-8 (22) were increased in patients with HNSCC compared with the control group (21) . In contrast to the angiogenesis-related proteins, which increased with tumour progression, angiogenin and TIMP1 were found to decrease with disease progression. One study which supports this finding is that of Homer et al (25) who demonstrated a lower serum angiogenin expression associated with locoregional disease recurrence in HNSCC. However, Ruokolainen et al (26) reported that high levels of TIMP1 are associated with tumour progression. The investigations showed an increased expression of TIMP1 in serum and tumour tissue in patients with stage T3 and T4 tumours compared with stage T1.
Furthermore, in the current study a higher expression of angiogenin and TIMP1 in tumour and associated nodal tissue compared with healthy control tissue was demonstrated, which is in agreement with the study by Charoenrat et al (24) who investigated levels in tumours compared with normal mucosa and also found a significant correlation between the levels of MMP-9 and TIMP1 with advanced T stage. A number of angiogenic factors have also been shown to differ between tumour and normal tissue, and with disease stage including uPA and its inhibitor, cxcl16, endothelin, IGFBP-1 which all increase with tumour progression. The role of these factors have also been studied in other malignancies including colon (27, 28) , renal cell (29) , ovarian (30) and gastric cancer (31) . However, there is little evidence for their role in HNSCC, suggesting that the role requires further elucidation.
Roesch-Ely et al (32) have carried out proteomic analysis on both tumour and adjacent healthy mucosa and found that 72% of the healthy mucosa adjacent to the tumour had a significant association between aberrant profiles and tumour relapse events. In the current study the expression of angiogenesisrelated proteins in the adjacent normal mucosa compared with that of the tumour tissue, metastatic node and healthy control tissue support the fact that although the adjacent mucosa may have a normal appearance, molecular events have occurred which are influencing protein production and could be important for subsequent tumour development.
In conclusion, many angiogenesis-related proteins may be involved in the growth, spread and progression of laryngeal tumours and tissues which may have a clinically normal appearance are likely to be part of the affected tumour zone. Further investigation into the level of expression of specific factors in a larger cohort of patients is required to validate the findings of this study.
